Diffuse large B-cell lymphoma (DLBCL) is an aggressive type of non-Hodgkin lymphoma. It is the most common type of non-Hodgkin lymphoma across the world, accounting for about 22% of all newly diagnosed cases. However, up to 40% of patients with DLBCL will either relapse or become refractory to initial therapy. Treatment options were limited for these patients until the approval of CD19-targeted chimeric antigen receptor (CAR) T-cell therapy tisagenlecleucel and axicabtagene ciloleucel. CAR T-cell therapies have emerged as promising treatment options for patients with relapsed or refractory DLBCL.
The Global Relapsed or Refractory Diffuse Large B-cell Lymphoma Market is estimated to be valued at US$ 1777.75 Bn in 2024 and is expected to exhibit a CAGR of 16% over the forecast period 2024 To 2031.
Key Takeaways:
Key players operating in the Relapsed or Refractory Diffuse Large B-cell Lymphoma are Sharp Corp., LG, Samsung, Hitachi, and Panasonic. These players are largely focused on strengthening their product portfolios through continuous research and development for introducing innovative and more effective treatment options. Some of the major opportunities in the market include increasing investment by public and private players in development of novel therapies, rising awareness about treatment options, and strengthening of healthcare infrastructure across developing regions. Geographically, North America is expected to dominate the global market owing to the high adoption of CAR T-cell therapies. However, Asia Pacific is anticipated to witness fastest growth over the forecast period driven by increasing research activity and improving access to novel treatments in countries like China and India.
Market Drivers:
The increasing product approvals is one of the major factors driving the growth of Relapsed Or Refractory Diffuse Large B-Cell Lymphoma Market Demand. The U.S. FDA approval of Novartis’ Kymriah and Gilead/Kite Pharma’s Yescarta has provided new treatment options for patients with relapsed or refractory diffuse large B-cell lymphoma who failed conventional chemotherapy.
Market Restrains:
High treatment cost of CAR T-cell therapies poses a major challenge to wider adoption and market growth. The average cost of CAR T-cell therapy in the U.S. ranges between $373,000 to $475,000 which limits its reach. Also, these therapies are also associated with severe side effects that require intensive management, adding to the overall cost burden. This remains a major restraint for the market.
Segment Analysis
The relapsed or refractory diffuse large B-cell lymphoma market is segmented into chemotherapy, targeted therapy, immunotherapy and others. The targeted therapy segment dominated the market in 2024 as monoclonal antibody drugs like brentuximab vedotin and polatuzumab vedotin showed promising results in clinical trials. These drugs have innovative mechanism of action and have less side effects compared to chemotherapy.
Global Analysis
North America region held the largest share in the relapsed or refractory diffuse large B-cell lymphoma market in 2024 due to advanced healthcare infrastructure and presence of key market players. The region dominated the global market due to high diagnosis rate along with increasing targeted therapies approval and dominance of US pharmaceutical companies in drug development. Asia-Pacific is anticipated to grow at the fastest rate during the forecast period owing to rising healthcare spending, developing healthcare infrastructure, increasing awareness about lymphoma.
Get more insights on Relapsed Or Refractory Diffuse Large B-Cell Lymphoma Market
